A Study of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors

Inclusion Criteria: 1. Previously receiving ≥ first-line regimen chemotherapy; 2. Age over 3 years old and less than 14 years old; 3. The expected survival period is more than 3 months; 4. ECOG≤2; 5. Vital organ function is satisfied: cardiac ultrasound indicates cardiac ejection fraction ≥ 50%, no obvious abnormality in ECG; blood oxygen saturation ≥ 90%; creatinine clearance calculated by Cockcroft-Gault formula ≥ 40ml/min; ALT and AST ≤ 3 times the normal range, total bilirubin ≤ 2.0 mg / dl; 6. Blood routine: Hgb≥80g/L, ANC≥1×109/L, PLT≥50×109/L; There are measurable target lesions. Exclusion Criteria: 1. Liver and kidney function: * Total bilirubin \> 2 x ULN (Gilbert syndrome \> 3 x ULN) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \> 3 × ULN * Serum creatinine clearance \>60mL/min 2. Serological examination: * Absolute neutrophil count (ANC) \<0.75x109/L * Platelet count (PLT) \<50x109/L 3. Active hepatitis B (HBV-DNA \> 1000 copies / ml), hepatitis C, or uncontrolled infection; 4. The number of days of chemotherapy medication and the administration of hormones below 5mg is ≤3, and the number of days of withdrawal of hormones greater than 5mg is ≤5; 5. Active CNS disease (tumor cells in CSF); 6. Intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular internal coagulation; 7. creatinine \> 1.5 times the upper limit of normal or ALT / AST \> 3 times the upper limit of normal or bilirubin \> 2 times the upper limit of normal; 8. The New York Heart Association (NYHA) is classified as Level III or higher; 9. Uncontrolled diabetes; 10. With other uncontrolled diseases, the investigator believes that it is not suitable for joining; 11. Any situation that the investigator believes may increase the risk of the subject or interfere with the test results.